Cargando…

Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis

BACKGROUND: According to the mechanisms of action, combination therapy of anabolic and antiresorptive agents may produce more effect for the treatment of osteoporosis. However, the combination therapy of anabolic agents and bisphosphonates reports no benefit and even reduced the anabolic effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Shenghan, Wang, Lifan, Wang, Yiwen, Jiang, Yunduo, Liu, Jingwei, Wang, Yansong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392516/ https://www.ncbi.nlm.nih.gov/pubmed/29384970 http://dx.doi.org/10.1097/MD.0000000000009534

Ejemplares similares

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018)

Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials
por: Lou, Shenghan, et al.
Publicado: (2018)

Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022)

Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes
por: Vilaca, Tatiane, et al.
Publicado: (2023)

The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men
por: Schwarz, Peter, et al.
Publicado: (2011)

New Antiresorptive Therapies for Postmenopausal Osteoporosis
por: Choi, Hee-Jeong
Publicado: (2015)

Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003–2021
por: Wadhwa, Harsh, et al.
Publicado: (2023)

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
por: Paton‐Hough, Julia, et al.
Publicado: (2018)

Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives
por: Zhang, Chenggui, et al.
Publicado: (2021)

Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA
por: Bagi, Cedo M., et al.
Publicado: (2015)

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
por: Taguchi, Akira, et al.
Publicado: (2017)

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review
por: Qayoom, I., et al.
Publicado: (2018)

Plumbagin is a NF-κB-inducing kinase inhibitor with dual anabolic and antiresorptive effects that prevents menopausal-related osteoporosis in mice
por: Shen, Gengyang, et al.
Publicado: (2022)

Antiresorptive Agents are More Effective in Preventing Titanium Particle‐Induced Calvarial Osteolysis in Ovariectomized Mice Than Anabolic Agents in Short‐Term Administration
por: Fu, Guangtao, et al.
Publicado: (2018)

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis
por: Migliorini, Filippo, et al.
Publicado: (2022)

A review of anabolic therapies for osteoporosis
por: Lane, Nancy E, et al.
Publicado: (2003)

Anabolic Therapies in Osteoporosis and Bone Regeneration
por: Russow, Gabriele, et al.
Publicado: (2018)

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
por: Holen, I, et al.
Publicado: (2006)

Two Cases of External Auditory Canal Osteonecrosis in Patients on Antiresorptive Therapy for Osteoporosis
por: Kumar, Shejil, et al.
Publicado: (2023)

Composition and Properties of Saliva in Patients with Osteoporosis Taking Antiresorptive Drugs
por: Sobczak-Jaskow, Hanna, et al.
Publicado: (2023)

Anabolic therapy for osteoporosis: update on efficacy and safety
por: Bandeira, Leonardo, et al.
Publicado: (2022)

Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials
por: Lou, Shenghan, et al.
Publicado: (2016)

Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients
por: Morishita, Kota, et al.
Publicado: (2022)

Vitamin D Receptor Gene Polymorphisms Affect Osteoporosis-Related Traits and Response to Antiresorptive Therapy
por: Mondockova, Vladimira, et al.
Publicado: (2023)

Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs
por: del Real, Álvaro, et al.
Publicado: (2022)

P02 When should we stop the antiresorptive medications in patients with osteoporosis?
por: Mohareb, Marwa, et al.
Publicado: (2023)

Anabolic treatments for osteoporosis in postmenopausal women
por: Hassan, Neelam, et al.
Publicado: (2021)

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
por: Ottewell, PD, et al.
Publicado: (2006)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials
por: Lou, Shenghan, et al.
Publicado: (2016)

Disulfiram Attenuates Osteoclast Differentiation In Vitro: A Potential Antiresorptive Agent
por: Ying, Hua, et al.
Publicado: (2015)

Antiresorptive Agents Increase the Effects of Exercise on Preventing Postmenopausal Bone Loss in Women: A Meta-Analysis
por: Zhao, Renqing, et al.
Publicado: (2015)

Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis
por: Dou, Ce, et al.
Publicado: (2021)

Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
por: Eastell, Richard, et al.
Publicado: (2022)

Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis
por: He, Jianbo, et al.
Publicado: (2019)

Genome-wide association study of osteonecrosis of the jaw in Danish patients receiving antiresorptive therapy for osteoporosis: A case-control study
por: Pedersen, Alma B., et al.
Publicado: (2022)

Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
por: Ekholm, Heidi M., et al.
Publicado: (2021)

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis
por: Zhang, Zheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3l93lblr9rortra6ln8eubi83d